BeStock  
Stocks › Biotechnology › XENE

Xenon Pharmaceuticals XENE

US equityMarket cap rank #2343Biotechnology
$37.57 −$0.45 (-1.18%)
Market closed · Oct 6, 12:20 am ET · Last extended-hours $37.72 +0.40%
Open$38.02
Prev close$38.02
Day range$37.00 – $38.23
Volume1.70M
Market cap$3.64B
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±5.1%last 16 reports
Closed higher4 of 1625% of the time
Best reaction+8.3%
Worst reaction-17.4%

Stock move on the day after each report

+8.3%2023/Q2-6.7%2023/Q3-0.8%2023/Q4-4.6%2024/Q1-3.2%2024/Q2-3.3%2024/Q3-3.4%2024/Q4-17.4%2025/Q1+5.5%2025/Q2-4.9%2025/Q3+0.8%2026/Q1-1.8%2026/Q2
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q26 Aug 2026After Market±8.8%-1.84%Within range
2026/Q17 May 2026After Market±10.1%+0.79%Within range
2025/Q33 Nov 2025After Market±11.0%-4.94%Within range
2025/Q211 Aug 2025After Market±9.9%+5.51%Within range
2025/Q112 May 2025After Market±9.8%-17.43%Bigger than priced
2024/Q427 Feb 2025After Market±21.3%-3.37%Within range
2024/Q312 Nov 2024After Market±9.7%-3.27%Within range
2024/Q28 Aug 2024After Market–-3.19%–
2024/Q19 May 2024After Market±11.3%-4.59%Within range
2023/Q429 Feb 2024After Market±11.5%-0.76%Within range
2023/Q38 Nov 2023After Market±12.8%-6.69%Within range
2023/Q29 Aug 2023After Market±11.8%+8.29%Within range
2023/Q19 May 2023After Market±12.3%-5.51%Within range
2022/Q41 Mar 2023After Market±12.8%-7.39%Within range
2022/Q38 Nov 2022After Market±17.2%-6.61%Within range
2022/Q29 Aug 2022After Market±10.9%+0.84%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Latest reported quarter: ANNUAL, ended Dec 2025

Revenue$7.50M
Operating profit-$373.07M-33.6% YoY
Net profit-$345.91M-47.6% YoY
Diluted EPS-$4.36-44.9% YoY

Profitability & balance sheet

Operating margin-4,974.3%
Net margin-4,612.1%
Return on equity-43.6%
Return on assets-41.5%
Return on invested capital-46.5%
Current ratio21.02

Discussion

No comments yet — be the first to weigh in on XENE.

Leave a comment

Scroll to Top